High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine ; volume:22 ; number:1 ; day:3 ; month:1 ; year:2022 ; pages:1-13 ; date:12.2022
BMC cancer ; 22, Heft 1 (3.1.2022), 1-13, 12.2022
- Urheber
-
Li, Liru
Ai, Lin
Jia, Lin
Zhang, Lei
Lei, Boya
Zhang, Qingyuan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-021-09131-6
- URN
-
urn:nbn:de:101:1-2022042120502610707494
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Li, Liru
- Ai, Lin
- Jia, Lin
- Zhang, Lei
- Lei, Boya
- Zhang, Qingyuan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
Prognostic value of neutrophile-to-lymphocyte ratio (NLR) and lactate dehydrogenase (LDH) levels for geriatric patients with COVID-19
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Prognostic value of systemic inflammatory factors NLR, LMR, PLR and LDH in penile cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
Prognostic value of neutrophile-to-lymphocyte ratio (NLR) and lactate dehydrogenase (LDH) levels for geriatric patients with COVID-19
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Prognostic value of systemic inflammatory factors NLR, LMR, PLR and LDH in penile cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
Prognostic value of neutrophile-to-lymphocyte ratio (NLR) and lactate dehydrogenase (LDH) levels for geriatric patients with COVID-19
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Prognostic value of systemic inflammatory factors NLR, LMR, PLR and LDH in penile cancer